Rhythm Pharmaceuticals (RYTM) Cost of Revenue (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Cost of Revenue data on file, last reported at $7.2 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 96.19% year-over-year to $7.2 million in Q1 2026; TTM through Mar 2026 was $23.0 million, a 61.86% increase from a year earlier, with the FY2025 full-year figure at $19.5 million, up 45.81% from the prior year.
• Cost of Revenue for Q1 2026 stood at $7.2 million, up from $4.8 million in the prior quarter.
• Over the last five years, Cost of Revenue for RYTM reached as high as $7.2 million in Q1 2026 and fell as low as $230000.0 in Q1 2022.
• Historically, Cost of Revenue has averaged $3.0 million across 5 years, with a median of $2.9 million in 2024.
• Across the five-year window, Cost of Revenue surged 5650.0% in 2022 and rose 17.14% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $1.0 million in 2022, then surged by 214.49% to $3.2 million in 2023, then rose by 17.14% to $3.8 million in 2024, then gained by 26.8% to $4.8 million in 2025, then surged by 49.04% to $7.2 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $7.2 million in Q1 2026, $4.8 million in Q4 2025, and $5.5 million in Q3 2025.